Navigation Links
GranuFlo Lawsuit News: Bernstein Liebhard LLP Notes Recent Surge of FDA Drug Recalls

New York, NY (PRWEB) August 14, 2014

A U.S. Food and Drug Administration (FDA) initiative that allows public access to product recall information reveals that actions similar to one that has since prompted thousands of GranuFlo lawsuits ( have increased dramatically over the past few years, Bernstein Liebhard LLP reports.

According to a recent report from the Regulatory Affairs Professionals Society, a total of 499 drug recalls were issued by the FDA in 2012; the same year a Class I recall of GranuFlo and NaturaLyte, two acid concentrates used in dialysis, was announced. The FDA issued more than 1,220 recalls in 2013, and another 836 have already been announced in 2014, according to an article published on August 11th.*

Following the GranuFlo recall of 2012, court documents show thousands of lawsuits now filed on behalf of individuals who received the dialysis medications, which are distributed by Fresenius Medical Care. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

“As product recalls continue to be announced by the FDA, our Firm continues to hear from individuals who suffered injuries allegedly caused by dialysis medications affected by the 2012 GranuFlo recall,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case reviews to individuals who were allegedly injured by products affected by the 2012 GranuFlo and NaturaLyte recall, as well as others involved in similar recalls.

GranuFlo Lawsuits

In June 2012, the FDA granted a Class I recall of GranuFlo and NaturaLyte after determining that use of the dialysis drugs may pose a risk of serious injury or death. This action followed an Urgent Product Notification issued by Fresenius two months earlier that noted its products’ potential to cause serious cardiovascular problems. Since then, thousands of GranuFlo and NaturaLyte lawsuits were filed on behalf of individuals who allegedly suffered cardiac arrest, heart attacks, strokes, sudden cardiac death and other side effects caused by the dialysis medications. The majority of claims have now been centralized in the U.S. District Court, District of Massachusetts, where a multidistrict litigation has been established.

GranuFlo recall lawsuits now filed in Massachusetts accuse Fresenius of failing to adequately warn dialysis patients about the potential for its products to cause serious heart problems that may turn fatal. Plaintiffs further allege that the company continued to aggressively market GranuFlo and NaturaLyte even after it became aware of its potential to cause harm to patients.

In addition to Fresenius lawsuits now filed in the District of Massachusetts, court records indicate that nearly 4,000 claims have been consolidated at the state court level in Middlesex County Superior Court. (In re: Consolidated Fresenius Cases, No. MICV2013-03400-O).

Individuals who were allegedly harmed by GranuFlo or NaturaLyte may be eligible to file their own lawsuit against Fresenius. Learn more ( about the FDA’s GranuFlo recall of 2012 by visiting Bernstein Liebhard LLP’s website, or call 800-511-5092 to arrange for a free, no-obligation case review.

*; Regulatory Affairs Professional Society, August 11, 2014.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Louisiana Attorney General Files Complaint Against GranuFlo Manufacturer, Baron and Budd Reports
2. Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs
3. GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports
4. GranuFlo Lawsuit Filings Near 2,000 in Federal Massachusetts Litigation Two Years after Dialysis Recall, Bernstein Liebhard LLP Reports
5. GranuFlo Lawsuits News: Missouri Federal Court Returns Multi-Plaintiff Case to State Court, Rottenstein Law Group LLP Reports
6. GranuFlo Lawsuits Move Forward, as Federal Court Adopts Master Complaint for all Claims Filed in Wake of GranuFlo and NaturaLyte Recall, Bernstein Liebhard LLP Reports
7. Federal GranuFlo Lawsuits Move Forward with Scheduling of First Status Conference of the New Year, Bernstein Liebhard LLP Reports
8. Bernstein Liebhard LLP Publishes New GranuFlo Lawsuit Website for Individuals Allegedly Affected by 2012 Dialysis Drug Recall
9. GranuFlo Lawsuit News: Bernstein Liebhard LLP Notes Filing of New Joint Motion in Federal GranuFlo Recall Litigation
10. More Than 430 Cases Now Filed in Federal GranuFlo Lawsuit Litigation, Bernstein Liebhard LLP Continues to Investigate Dialysis Claims
11. Bernstein Liebhard LLP Launches New GranuFlo Lawsuit Website for Individuals Allegedly Injured by Recalled Dialysis Medications
Post Your Comments:
(Date:10/13/2015)... , ... October 13, 2015 , ... ... review of Anik Singal's newly launched "Publish Academy" training course . Singal's ... business opened for enrollment today, and marketers around the Internet are weighing in ...
(Date:10/13/2015)... ... October 13, 2015 , ... T-System and Centegra ... than 59,000 emergency department visits per year, today announced the successful and rapid ... improve clinical, operational and financial outcomes. , In less than four ...
(Date:10/13/2015)... ... , ... Local Gold’s Gym franchise owner, Bryce Berry, received the Visionary of ... owns and operates Gold's Gym Cheyenne in Cheyenne, Wyoming, received the award ... States. A brand leader in global fitness, Gold’s Gyms are located worldwide. Every fitness ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... Affinity have developed valuable new strategies for enrolling and serving insurance consumers who ... to obtain health insurance and pay monthly premiums. In “Health Plan Engagement Strategies: ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... team: Debbie Vereb has been named the organization’s Executive Vice President of ... have been hired to key leadership roles in the company. , Debbie Vereb’s ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... MENLO PARK, Calif. , Oct. 12, ... of R&D and Chief Scientific Officer of ... leading biotechnology company in the emerging field ... BioPharma Dealmakers webcast, sponsored in part by ... medicine. Dr. Lebkowski will discuss the progress ...
(Date:10/12/2015)... 12, 2015 The global infertility treatment ... million by 2020 from USD 1,822.32 million in ... and 2020. By product, the market includes antivibration ... systems, micromanipulator systems, ovum aspiration pumps, sperm analyzer ... market is segmented into in vitro fertilization, artificial ...
(Date:10/12/2015)... -- Elbit Imaging Ltd. ("EI" or the "Company") ... of directors approved a program to repurchase up to NIS ... Notes and Series I Notes, which are traded on the ... Company will have a significant preference to the purchase Series ... time in the open market on the Tel Aviv Stock ...
Breaking Medicine Technology: